STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Diamyd Medical (NASDAQ:DMYDY) (STO:DIAMB) announced today that it has received one FDA question relating to the US Phase III IND application for Diamyd® in treatment of type 1 diabetes. The question has been answered with additional documentation and the FDA now has 30 days to respond.
